USPTO serial 99409682
NEURONAL DEFENSE
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PHILLIPS, WENDELL SHARMAN
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with NEURONAL DEFENSE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monte L. Falcoff
Monte L. Falcoff Harness, Dickey & Pierce, P.L.C.100 Bloomfield Hills ParkwaySuite 200Bloomfield Hills, MI 48304Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Natural dietary supplements comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function; Pharmaceutical preparations comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration ; and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 18, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 23, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 23, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 17, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 26, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 16, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 16, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 16, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 19, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 19, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 19, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 30, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 16, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 16, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 16, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 24, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 24, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 24, 2025 | NWAP | NEW APPLICATION ENTERED | — |